Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activ: Final Results of the RHAPSODY Trial
2019
Keywords:
-
Correction
-
Source
-
Cite
-
Save
35
References
0
Citations
NaN
KQI